Top Biotech Companies (3,704)
Liquidia is a biopharmaceutical company developing and commercializing therapies for rare cardiopulmonary diseases, particularly pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Its work combines proprietary formulations, innovative drug-delivery methods, and PRINT particle-engineering technology to improve therapeutic performance. The company also collaborates with pharmaceutical partners and focuses on addressing unmet needs for patients and healthcare providers worldwide.
URUS Group is a global holding company dedicated to serving dairy and beef cattle producers worldwide. It connects several agricultural organizations to provide cutting-edge genetic solutions, reproductive innovation, data-driven herd management, and consulting services. The company focuses on improving the productivity and sustainability of commercial dairy and beef operations to create better cows for a better world.
We are entering a new era of medicine, where cancer is treated with cellular therapies: living, smart, targeted drugs. While enormous strides have been made, especially in hematologic cancers, the full promise of these therapies still lies ahead. Cell-based immunotherapies have yet to show substantial benefit in solid tumors, which represent the vast majority of cancers. Our goal is nothing...
Covestro is one of the world’s leading manufacturers of high-quality polymer materials and their components. With its innovative products, processes and methods, the company helps enhance sustainability and the quality of life in many areas. Covestro supplies customers around the world in key industries such as mobility, building and living, as well as the electrical and electronics sector. In addition,...
Covestro's Top Stability & Growth Strengths
Strong Market Position & Advantage: Feedback suggests Covestro holds top-tier, often #1, positions in polycarbonate and select specialty coating precursors, underpinned by global, multi-site capacity. Evidence also points to recognized strategic importance and deep technology/application know-how across polyurethane inputs, even if not the largest in every sub-market.
Future-Ready Strategy: Feedback suggests the company has clear climate-neutrality and circularity targets and is executing a multi-year transformation program alongside selective specialty acquisitions. These actions aim to shift the mix toward higher-value applications and position the portfolio for recovery when pricing and demand normalize.
Investor Backing & Capital Strength: Feedback suggests majority ownership by ADNOC/XRG and a completed capital increase provide stronger financial backing and optionality for investment. Regulatory clearances and integration steps indicate committed sponsorship that could support medium-term growth initiatives.
Centrient Pharmaceuticals is a global business-to-business manufacturer of foundational medicines, including antibiotics, next-generation statins, and anti-fungals. The company leverages proprietary enzymatic biotechnology to produce active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms (FDFs). Headquartered in the Netherlands, Centrient focuses on sustainable, quality-driven manufacturing and supply chain security, serving as a key partner in the global healthcare system to improve...
ARTBIO is a clinical-stage radiopharmaceutical biotechnology company focused on developing a new class of alpha radioligand therapies (ART). Our unique patient-centric approach is underpinned by a deep understanding of cancer biology and the infrastructure needed to effectively design, manufacture, and distribute our therapies.
CSL is a leading global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency, dialysis and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our businesses, CSL Behring,...
Novotech is a leading Asia-Pacific biotech specialist CRO and consists of two operating brands, "Novotech" and "PPC". Novotech is a full-service clinical CRO with labs, phase I facilities, and drug development consulting services.
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture...
Thermo Fisher Scientific's Top Stability & Growth Strengths
Strong Market Position & Advantage: Thermo Fisher’s scale and breadth—largest revenue in 2025 (~$44.6B), leadership across a moderately consolidated tools market, and a top‑tier market value—support clear category leadership. Third‑party benchmarking and peer comparisons (e.g., relative to Danaher) reinforce its platform advantage.
Diversified Revenue Streams: A broad, integrated portfolio spanning instruments, consumables, diagnostics, distribution, and biopharma services (PPD, Patheon) drives multiple revenue engines and customer stickiness. Recurring consumables/services and distribution contribute steady mix that helps smooth cycles.
Innovation-Driven Growth: Recent product launches (e.g., Glacios 3 Cryo‑TEM, TSQ Certis) and the NVIDIA collaboration to accelerate AI‑enabled and increasingly autonomous lab systems indicate continued innovation momentum. These initiatives position the platform to capture next‑gen workflow demand.
Oura is an award-winning and fast-growing startup that helps people track all stages of sleep and activity using the Oura Ring and connected app. By providing daily feedback and practical steps to inspire healthy lifestyles, we've helped hundreds of thousands of people improve their sleep, understand their bodies, and transform their health. We’re on a mission to empower every person...
Ōura's Top Stability & Growth Strengths
Strong Market Position & Advantage: Independent industry tracking places Oura as the dominant smart‑ring vendor, maintaining leadership even as new entrants scale. Shipment growth for the category accelerated while Oura remained the leader.
Strong Revenue Growth: Company and third‑party reports indicate revenue roughly doubled in 2024 with guidance to surpass prior levels in 2025, alongside a sharp acceleration in unit sales. Recent disclosures cite more than half of cumulative sales occurring in the prior year.
Investor Backing & Capital Strength: Late‑2025 fundraising at a significantly higher valuation and substantial capital raised point to strong investor confidence. Added partnerships and ecosystem integrations, including glucose insights collaborations, reinforce access to resources.
Over 5,000 members, 40 nobel laureates, and YOU! The American Society for Cell Biology (ASCB) is an inclusive, international community of scientists in cell biology and biomedical research. We are dedicated to advancing scientific discovery, advocating sound research policies, improving education, promoting professional development, and increasing diversity in the scientific workforce. Our membership ranges from undergraduate students to thought leaders in cell...
The OmniAb discovery platform provides pharmaceutical industry partners access to diverse antibody repertoires and high-throughput screening technologies to enable discovery of next-generation therapeutics.
HALO Precision Diagnostics™ changes patient lives and outcomes through early detection of the leading causes of death with precision diagnostics. We accomplish this with a personalized diagnostic ensemble including advanced imaging, genomics, non-invasive liquid biomarkers, and community-based data at scale combined with deep learning algorithms. By optimizing all these solutions under the HALO Diagnostics platform, we provide rapid, precise, actionable...
Dianthus is a biotechnology company dedicated to designing and delivering the next generation of best-in-class monoclonal antibodies with improved selectivity and potency. Led by a multidisciplinary team of seasoned biotech entrepreneurs and scientists, we are pioneering selective antibodies of validated and emerging complement targets to allow people with rare and severe autoimmune diseases live healthier lives to their fullest potential.
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. We discovered and developed the first medicines to treat the underlying cause of cystic fibrosis (CF), a rare, life-threatening genetic disease. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs focused...
Vertex Pharmaceuticals's Top Stability & Growth Strengths
Strong Market Position & Advantage: Company materials depict Vertex as a leader with near‑dominance in cystic fibrosis and first‑mover approvals in CRISPR‑based gene editing. This is supported by broad real‑world CF impact and landmark authorizations for Casgevy.
Strong Revenue Growth: Reported year‑over‑year revenue growth in 2025 and raised guidance for 2026 indicate ongoing momentum. Quarterly performance aligned with or exceeded guidance during the year, underscoring execution against growth plans.
Diversified Revenue Streams: Early contributions in 2025 from Alyftrek, Journavx, and Casgevy, with management signaling higher non‑CF revenues in 2026, show a broadening base beyond CF. Guidance highlighting non‑CF contribution points to increasing mix diversification over the near term.
Oxford BioTherapeutics (OBT) is a clinical stage oncology company based in Oxford, UK; San Jose, CA and Morristown, NJ, USA, with a pipeline of first-in-class immuno-oncology (IO) and antibody-drug conjugate (ADC) based therapies designed to fulfil major unmet patient needs in cancer therapeutics. Our lead asset, OBT076, is an Antibody Drug Conjugate (ADC) in Phase 1b clinical development. OBT076's...
ImmunEdge is a biopharmaceutical company committed to developing novel therapeutics for patients with serious or life-threatening diseases. With a highly experienced team of experts in immunology and drug development, we are pioneering innovative approaches to target and modulate key molecular pathways that regulate the immune response.
BeiGene is a global biotechnology company that is developing and commercializing innovative and affordable oncology medicines to improve treatment outcomes and access for far more patients worldwide. With a broad portfolio, we are expediting development of our diverse pipeline of novel therapeutics through our internal capabilities and collaborations. We are committed to radically improving access to medicines for far more...
BeiGene's Top Stability & Growth Strengths
Strong Revenue Growth: Financial results show rapid, multi‑year top‑line increases with continued quarterly acceleration and raised full‑year guidance.
Strong Market Position & Advantage: Product performance indicates leadership in BTK inhibitors, with BRUKINSA establishing class momentum supported by head‑to‑head data and broad global approvals.
Innovation-Driven Growth: Pipeline breadth, significant R&D investment, and multiple recent regulatory approvals demonstrate an innovation engine fueling new indications and assets.
Ataraxis is an AI precision medicine company transforming cancer diagnostics and patient outcomes through the power of AI. We are addressing previously unsolvable problems in cancer prognosis and treatment selection through cutting-edge foundation models and multi-modal data. Our first clinically validated offering, Ataraxis Breast, is the world’s first AI-native prognostic/predictive test for breast cancer and provides greater accuracy than standard...
Enzyme design is the next grand challenge. Nature has spent billions of years evolving the enzymes we use today. Now we must design the enzymes of tomorrow. Fusing generative AI with experiment creates the opportunity to achieve this. Success will change the way we live, making better use of natural inputs and byproducts, reducing energy requirements, delivering life-changing therapies and providing...


















.jpg)














